###### Significance of this study

What is already known about this subject?
=========================================

-   The EGFR pathway became the focus of therapy development over the last few years, as the activated pathway drives cancer progression.

-   Anti-EGFR inhibitors, like cetuximab and panitumumab, have shown clinical benefit in metastatic colorectal cancer.

-   Activating *KRAS* mutations are established as negative predictor for response.

-   Activating *KRAS* mutations, or mutations in other key molecules (*BRAF*, *PI3KCA*), cannot fully explain the extent of non-response in the patient population and, therefore, other causes for non-response need to be identified.

What are the new findings?
==========================

-   Combined transcriptional profiling of oncogenic mutations allows the identification of patients with an active EGFR-signalling pathway that could benefit from downstream pathway inhibition.

-   Patients with a *BRAF* mutation display a distinct expression pattern.

-   Mechanisms other than oncogenic mutations can cause a similar activation of the pathway and result in a similar transcriptional pattern.

-   The development of activated pathway signature, as described here, allows the identification of all patients who have a similar phenotype as patients with oncogenic mutations. The signature is, therefore, more comprehensive and predictive than the mutation status alone.

###### Significance of this study

How might it impact on clinical practice in the foreseeable future?
===================================================================

-   A better understanding of the underlying mechanism of response to anti-EGFR therapies will help to further personalise medicine and increase benefit.

-   Our findings, and other published reports, demonstrate that expression signatures measuring pathway activation can identify patients who are sensitive to a pathway inhibition, and these signatures seem superior to measuring the mutation status alone. This observation should be confirmed in additional clinical studies.

-   The development and use of such signatures might be of special interest when less well-characterised pathways are targeted, and knowledge about predictive markers is limited.

Introduction
============

The epidermal growth factor receptor (EGFR) is a member of the ERBB family of receptors that plays a key role in cell proliferation, adhesion and migration.[@b1; @b2; @b3] The EGFR downstream intracellular signal transduction pathways include components of the RAS/mitogen-activated protein kinase (*MAPK*), phosphatidyl inositol 3-kinase (*PI3K*), signal transducer and activator of transcription, protein kinase C and phospholipase D pathways.[@b4]

Antibodies aimed directly at EGFR, such as cetuximab[@b5] and panitumumab,[@b6] have shown clinical benefit in metastatic colorectal cancer (CRC). However, only 20%--30% of these patients respond to EGFR inhibitors. The lack of clinical response to the EGFR pathway inhibitors in many patients has been partially attributed to downstream or parallel activation of the pathway.[@b7] Notably, KRAS and PIK3CA pathways can also be activated by other upstream receptors.

Molecular alterations that constitutively activate EGFR signal transduction have been associated with lack of response to cetuximab or panitumumab. *KRAS* mutations account for only 30%--40% of non-responders to EGFR targeting in colorectal cancer.[@b8; @b9; @b10; @b11; @b12; @b13] Patients with activating mutations in *BRAF*,[@b14] *PIK3CA* [@b15] [@b16] and *NRAS* [@b17] might also not respond to these antibodies. Finally, loss of PTEN protein expression, a phosphatase that inactivates the PI3KCA downstream signalling, may associate with the lack of response to cetuximab.[@b18]

DNA microarray-based gene expression signatures can define cancer subtypes, recurrence of disease and response to specific therapies using.[@b19] [@b20] Also, they have proved useful for the analysis of the activation of oncogenic pathways in cancer samples.[@b21] [@b22] It has recently been demonstrated that an *RAS* pathway signature is superior to *KRAS* mutation status for the prediction of dependence on RAS signaling, and can predict response to PI3KCA and RAS pathway inhibitors.[@b23]

We hypothesised that analysing independent gene expression profiles of diverse oncogenic mutations in *BRAF*, *KRAS* or *PIK3CA* may uncover signatures of activated EGFR pathway signalling. In this study, we analysed the gene expression pattern of a large number of patients, and built a model for identifying patients with activated EGFR-signalling pathways. Since detection of signalling deregulation can be linked to sensitivity to targeted therapies,[@b21] we posit that such profiles may be helpful in predicting the response of individual patients to EGFR pathway inhibitors.

Material and methods
====================

Patients
--------

For the training set, 381 fresh frozen tumour samples from patients with CRC were collected at four different hospitals (Institut Català d\'Oncologia, Leiden University Medical Center, Netherlands Cancer Institute, Slotervaart General Hospital). Most patients had stage II (n=205) and stage III (n=116) CRC; 51 patients had stage I and 8 patients stage IV cancer. Main characteristics of the patients are depicted in [table 1](#tbl1){ref-type="table"} and have also been described in reference[@b24] The validation study was performed on 80 tumour samples, 50 stage II and 30 stage III with similar patient characteristics as the training set ([table 1](#tbl1){ref-type="table"}). All tissue samples were collected from patients with appropriate informed consent. The study was carried out in accordance with the ethical standards of the Helsinki Declaration and was approved by the Medical Ethical Board of the participating medical centres and hospitals.

###### 

Clinico-pathological information and mutation status

                                   Training set, all samples n=381   Validation set, all samples n=80
  -------------------------------- --------------------------------- ----------------------------------
  Gender                                                             
   M                               209 (54.9)                        40 (50.0)
   F                               172 (45.1)                        40 (50.0)
  Age                                                                
   Median                          68 yrs                            75 yrs
  Localisation                                                       
   Left                            202 (53.0)                        31 (38.8)
   Right                           136 (35.7)                        30 (37.5)
   Rectum                          37 (9.7)                          8 (10.0)
   Unknown                         6 (1.6)                           11 (13.8)
  T-stage                                                            
   1                               4 (1.0)                           0 (0)
   2                               53 (13.9)                         2 (2.5)
   3                               296 (77.7)                        74 (92.5)
   4                               27 (7.1)                          4 (5.0)
   Unknown                         1 (0.3)                           0 (0)
  N-status                                                           
   N0                              259 (68.0)                        50 (62.5)
   N+                              121 (31.8)                        30 (37.5)
   Unknown                         1 (0.3)                           0 (0)
  Distal metastasis in follow-up                                     
   No                              299 (78.5)                        68 (85.0)
   Yes                             81 (21.3)                         12 (15.0)
   Unknown                         1 (0.3)                           0 (0)
  Stage                                                              
   1                               51 (13.4)                         0 (0.0)
   2                               205 (53.8)                        50 (62.5)
   3                               116 (30.4)                        30 (37.5)
   4                               8 (2.1)                           0 (0.0)
   Unknown                         1 (0.3)                           0 (0)
  Grade                                                              
   Good                            101 (26.5)                        8 (10.0)
   Moderate                        233 (61.2)                        52 (65.0)
   Poor                            45 (11.8)                         16 (20.0)
   Unknown                         2 (0.5)                           4 (5.0)
  *KRAS* mutation                                                    
   No                              266 (69.8)                        51 (63.7)
   Yes                             115 (30.2)                        29 (36.3)
  *BRAF* mutation                                                    
   No                              339 (89.0)                        76 (95)
   Yes                             42 (11.0)                         4 (5.0)
  *PI3KCA* mutation                                                  
   No                              337 (88.5)                        64 (80.0)
   Yes                             44 (11.5)                         16 (20.0)
  Any mutation                                                       
   No                              206 (54.1)                        40 (50.0)
   Yes                             175 (45.9)                        40 (50.0)

Mutational analysis
-------------------

Mutations in *BRAF* V600, *KRAS* codons 12, 13 and 61, and *PIK3CA* exons 9 and 20 were assessed in cDNA by Sanger sequencing of PCR products using primers with M13 tails after RT-PCR. (ServiceXS BV). V600E *BRAF* mutation were analysed after amplification of exon 15, using primers 5′-TGATCAAACTTATAGATATTGCACGA (upstream) and 5′- TCATACAGAACAATTCCAAATGC (downstream). *KRAS* whole coding region was analysed using primers 5′-AGGCCTGCTGAAAATGACTG (upstream) and 5′-TGGTGAATATCTTCAAATGATTTAGT (downstream). For *PIK3CA* the primers used were 5′-CCACGCAGGACTGAGTAACA (upstream) and 5′-GGCCAATCTTTTACCCAAGCA (downstream) for exon 9, and 5′-TGAGCAAGAGGCTTTGGAGT (uptstream) and 5′-AGTGTGGAATCCAGAGTGAGC (downstream) for exon 20. The Mutation Surveyor Software (SoftGenetics LLC) was used for sequence analysis.

Gene expression profiling and signature development
---------------------------------------------------

RNA isolation, amplification, labelling, the hybridisation to Agilent full-genome microarrays and data processing was performed as previously described.[@b24] Since all samples contained at least 40% tumour cells, we assumed that they were informative for tumour cell status. The reference comprised a pool of 44 CRC specimens and was processed and labelled in the same manner as the test samples.

Normalised gene expression ratios for every hybridisation were combined to produce a single gene expression profile per patient, using Matlab software (MathWorks, Inc, Natick, Massachusetts, USA). Development of each of the three oncogenic signatures was performed according to a 10-fold cross-validation strategy (CV10).[@b24] For each of the CV10 iteration, 10% of samples with an activating mutation and 10% of the wildtype samples were randomly excluded from the gene selection procedure and used for testing of the identified gene signatures. Using the remaining 90% of samples, each gene was scored for its association with the mutation status in the training procedure ([table 1](#tbl1){ref-type="table"}). Only genes with a p value \<0.05 (two-sided Student\'s t test) and a differential expression \>1.25 were ranked-ordered based on their p value, and used for subsequent signature construction. For increasing gene set (2, 3...500) a nearest centroid classification model was constructed and tested on the initially excluded 10% of samples.[@b25] Signature performance and individual gene p values were recorded, and the complete CV10 procedure was repeated a thousand times. The final optimal set of genes was determined by combing all CV10 results and selection of the minimal number of genes with the higher overall accuracy (combined sensitivity and specificity).

The selected set of optimal gene probes was used to score all tumour samples for their correlation with the *KRAS*, the *BRAF* and the *PI3KCA* signature (Suppl Table S1). Depending on whether the signature score exceeded a predefined threshold, a sample was classified as activated oncogenic or as wildtype-like. The signature thresholds were based on an optimal sensitivity to correctly identify all known oncogenic mutation carriers and all other samples that harboured the activating oncogenic signatures. For a comprehensive identification of tumours that harbour activating oncogenic mutation(s) in the EGFR-signalling pathway, the three individual *KRAS*, *BRAF* and *PIK3CA* oncogenic signatures were combined. In this combined model, the gene expression pattern of each tumour is scored for its association with all the three oncogenic mutation signatures and placed into a 3D plot. All signature-related gene expression data are available on the Agendia Research web site (<https://research.agendia.com>).

Signature validation in cetuximab-treated patients
--------------------------------------------------

Publicly available Affymetrix gene expression and clinical data from 80 samples from metastatic colon cancer patients who have been treated with cetuximab[@b12] were downloaded via the Gene Expression Omnibus with accession number GSE5851. Using all probes, the unsupervised K-means clustering with cityblock distance measurement can partition these 80 tumours into two groups: one group with 33% of samples and the other group with 67% of them. Clinical data regarding cetuximab treatment response were available for 68 patients. We could identify 49 of the 75 *KRAS* signature genes, 37 of the 59 *BRAF* signature genes and 34 of the 49 *PIK3CA* signature genes. The genes found on the Affymetrix arrays are highlighted in the Suppl Table S1. Readout of the signature scores on the Affymetrix data by the nearest centroid classifier methods was done in a similar fashion as used for the in-house Agilent microarray data. Samples were ranked according to the signatures scores and classified as activating oncogenic (n=22) and wildtype-like (n=46) based on the 33-percentile.

Additional analysis
-------------------

Ingenuity Pathways Analysis (IPA) software (Ingenuity Systems, Inc, Redwood City, California, USA), was used for gene ontology analysis and to analyse the profile genes for their potential-enriched biological and/or molecular function and signalling pathway involvement. A comparison was made between tumours harbouring no oncogenic mutations in *BRAF*, *KRAS* and *PI3KCA*, but classified as *activating oncogenic* (n=79) and tumours harbouring no oncogenic mutations in *BRAF*, *KRAS* and *PI3KCA* that were classified as wildtype-like (n=127). The false discovery rates-adjusted p values by Benjamini and Hochberg linear step-up procedure were calculated using a Student\'s t test. Differentially expressed genes (Benjamini and Hochberg-adjusted p value \<0.05) were input into IPA. To eliminate false protein--protein interactions in the pathway, only experimentally observed direct inhibitions and direct activations were considered. The area under Receiver Operating Characteristics (ROC) curve analysis was performed using MedCalc for Windows, version 9.6.4.0 (MedCalc Software, Mariakerke, Belgium).

Results
=======

Mutational analysis
-------------------

Three hundred and eighty-one primary colorectal tumours for which we have recently reported full genome gene expression analysis were analysed.[@b24] *KRAS* mutations were detected in 115 out of 381 cases (30.2%), *PIK3CA* mutations in 44 cases (11.5%) and *BRAF* mutations in 42 cases (11%) ([table 1](#tbl1){ref-type="table"}). Altogether, 175 tumours (45.9%) harboured at least one oncogenic mutation. The majority of *KRAS* mutations was found at codon 12 (22%), while 6.8% had mutation at codon 13, and 1.9% of patients harboured a mutation at codon 61. For *PI3KCA*, mutations were analysed in two previously reported 'hotspot' regions in exons 9 and 20, corresponding to the accessory (helical) and catalytic domains of *PIK3CA*, respectively. Mutations E542K/L, E545K/G, Q546K and D549E in exon 9 and mutations M1043I, A1046A and H1047L/R/Y in exon 20 were considered activating.[@b26] The majority of patients had mutations in exon 9 (7.1%) and only 4.7% in exon 20. One sample showed mutations in both exons. A limited overlap of mutations in different genes was observed. *BRAF* and *PIK3CA* mutations coexisted in nine cases (2.4%) and *KRAS* and *PI3KCA* mutations coexisted in 16 (4.2%) cases.

Development and validation of mutation signatures
-------------------------------------------------

*KRAS*, *BRAF* and *PIK3CA* mutation status was used to capture their gene-specific expression patterns. Using a 10-fold cross-validation procedure, three sets of genes were identified (Suppl Table S1) that were optimally suited for constructing an activating oncogenic signature for *KRAS* (75 genes, [figure 1A](#fig1){ref-type="fig"}), for *BRAF* (58 genes, [figure 1B](#fig1){ref-type="fig"}) and for *PIK3CA* (49 genes, [figure 1C](#fig1){ref-type="fig"}). None of the signatures correlated with disease relapse after a median follow-up time of 59.9 months (p values 0.572, 0.383, 0.441 for *KRAS*, *BRAF* and *PIK3CA*-signatures, respectively) indicating that the signatures are not prognostic. The *KRAS* oncogenic signature correctly classified 105 of the 115 tumours with a *KRAS* mutation (sensitivity 91.3%), and showed a specificity of 62% for an overall accuracy of 72.3% ([table 2](#tbl2){ref-type="table"}). No differences were evident between tumours harbouring codon 12 *KRAS* mutations or those harbouring codon 13 mutations (data not shown). The *BRAF* oncogenic signature correctly classified 38 of the 42 *BRAF*(+) tumour samples (sensitivity 90%), and classified 189 of the 206 tumours with no mutation as non-mutation-like (specificity 92%) resulting in an overall accuracy of 91% ([table 2](#tbl2){ref-type="table"}). *BRAF* mutations have been reported to be more frequent in patients with microsatellite instability (MSI-H).[@b27] Indeed, a correlation (Matthews correlation MCC=0.48) was observed between *BRAF* signature and the presence of MSI-H status. MSI status was known for 269 patients of whom 29 were classified as MSI-H (28). Fourteen (14/29=48.3%) of the MSI-H patients had a *BRAF* mutation and 20 (20/29=69%) were classified as *BRAF*-oncogenic by the signature ([figure 1B](#fig1){ref-type="fig"}). The *PIK3CA* signature showed a sensitivity of 75% with a specificity of 80% and an overall accuracy of 79% ([table 2](#tbl2){ref-type="table"}). Again, no evident differences were observed between exon 9 and exon 20 mutations (data not shown).

![*KRAS*, *BRAF* and *PIK3CA*-activating oncogenic gene signatures. Gene expression signatures specific for activating oncogenic mutations in (A) *KRAS* (75-gene signature), (B) *BRAF* (58-gene signature) or (C) *PIK3CA* (49-gene signature) genes. The heatmap represents relative gene expression levels of the signature genes across 381 colon tumour samples. Tumours are sorted according to the signature outcome (score). High gene expression is coloured in red, low expression in green. *Score*: tumour classified as activating oncogenic by the profile score are displayed as black boxes, tumours that are classified as wildtype-like are displayed as white boxes. *KRAS*, *BRAF* and *PIK3CA*: presence of the respective oncogenic mutations as measured by sequence analysis is indicted by corresponding black boxes. Any mutation: tumours carrying any of *KRAS/BRAF/PIK3CA* mutation are indicated by black boxes. *AREG*, *EREG*: expression levels of *AREG* and *EREG*. MSI, tumours with known MSI-H status.](gutjnl-2012-302423f01){#fig1}

###### 

Performance of *KRAS*, *BRAF* and *PIK3CA* mutation signatures in training and validation set

                                                                   *KRAS* signature   *BRAF* signature   *PI3K* signature
  ---------------------------------------------------------------- ------------------ ------------------ ------------------
  Training set (n=381)                                                                                   
   Sensitivity (%)                                                 91                 90                 75
   Specificity (%)                                                 62                 92                 80
   Accuracy (%)                                                    72                 91                 79
   Area under the ROC curve[\*](#table-fn1){ref-type="table-fn"}   0.846              0.948              0.853
   95% CI                                                          (0.801 to 0.883)   (0.912 to 0.972)   (0.803 to 0.894)
   z statistic                                                     16.338             23.254             11.868
   Significance level P (area=0.5)                                 \<0.0001           \<0.0001           \<0.0001
  Validation set (n=80)                                                                                  
   Sensitivity (%)                                                 93                 100                69
   Specificity (%)                                                 65                 93                 78
   Accuracy (%)                                                    77                 93                 75
   Area under the ROC curve (AUC)                                  0.872              0.981              0.812
   95% CI                                                          (0.770 to 0.941)   (0.886 to 1.000)   (0.686 to 0.904)
   z statistic                                                     8.579              24.350             4.818
   Significance level P (area=0.5)                                 \<0.0001           \<0.0001           \<0.0001

Calculated from training samples used for each signature (AUC).

The three signatures were validated in an independent dataset of 80 tumour samples ([table 2](#tbl2){ref-type="table"}). In this validation set, the performance of the signatures was in very good agreement with results from the training set.

The heatmap of the three tumour classification signatures ([figure 1](#fig1){ref-type="fig"}) suggested that the oncogenic signatures of the different mutations might have some degree of overlap. The proportion of overlapping genes in the minimal optimal gene sets (Suppl Tables S1, S2 and S3) was higher than chance (p value\<0.00001; hypergeometric statistics). Twenty-one overlapping genes for the *KRAS+PK3CA* signatures represent 28% of the components of the 75 *KRAS* gene signature and 43% of *PIK3CA* 49-gene signature are shared. The 11-gene overlap between *BRAF* and *PIK3CA* represents 22% of *PIK3CA* 49-gene signature, and 19% of the BRAF 58-gene signature. The overlap for *KRAS + BRAF* is lower: six genes (8% of *KRAS* 75 gene, 10% of *BRAF* 58 gene) (Table Suppl S3).

Values of area under the ROC calculated from all 381 samples for all mutations displayed highly significant values when compared with all mutations (p=0.0001; binomial exact test) suggesting that any mutation signature is able, to partially discriminate other types of mutations (supplementary table S4). Concordance analysis using κ statistics point to a modest overlapping of *BRAF* signature with *PIK3CA* mutations (AUC *PIK3CA* 0.65, κ=0.141) and of *KRAS* signature with *BRAF* mutations (AUC *BRAF* 0.76, κ=0.124).

Combined oncogenic pathway signature
------------------------------------

When using a multidimensional classification model (or combined oncogenic pathway signature), tumours displaying a gene expression pattern similar to any of the three oncogenic signatures were classified as '*activating oncogenic*', while tumours with a gene expression pattern that is negatively associated with all three oncogenic signatures are classified as wildtype-like and showed a *KRAS/BRAF/PIK3CA* wildtype profile ([figure 2](#fig2){ref-type="fig"}). The combined oncogenic pathway signature correctly predicted the presence of a mutation in *KRAS*, *BRAF* and/or *PIK3CA* for 158 of the 175 known mutation carriers (sensitivity of 90.3%) in the training set, and 37 of 40 known mutation carriers (sensitivity of 92.5%) in the validation set.

![Combined oncogenic pathway signature. Signature model for classification of 381 colon tumour samples based within a 3D space based on its association with the developed gene expression oncogenic signatures for *KRAS* (x-axis), *BRAF* (y-axis) and *PIK3CA* (z-axis). Each point represents a single tumour sample and is coloured according to its mutation status as measured by sequence analysis. The shape of the point represents that classification outcome based on the developed model in which triangles indicate tumours that are classified as mutation-like for the EGFR pathway by either *KRAS*, *BRAF* and/or *PIK3CA*; squares indicate tumours that are classified as non-mutation-like.](gutjnl-2012-302423f02){#fig2}

Interestingly, 79 of the 206 tumours that had no oncogenic mutations in *BRAF*, *KRAS* and *PI3KCA* were also classified as oncogenic based on their gene expression signatures (specificity of 61.7%) indicating that many *KRAS*, *BRAF* and *PI3KCA* wildtype patients share the same phenotype of an activated EGFR pathway as the patients with at least one activating mutation. To better understand why patients with no activating mutation in *KRAS*, *BRAF* and *PI3KCA* (n=79) were classified as *activating oncogenic*, we compared their gene expression pattern with the pattern of those patients who also had no detected oncogenic mutations in *KRAS*, *BRAF* and *PIK3CA*, but were classified as *wildtype-like* (n=127). IPA revealed that genes belonging to the ERK/MAPK pathway were significantly enriched in the combined signature (p=0.027). A more detailed analysis showed that there may be up to three alternate activating mechanisms in the set of wildtype patients having an oncogenic phenotype ([figure 3](#fig3){ref-type="fig"}). First, activation can occur directly through overexpression of key molecules in the pathway; indeed overexpression of *RAS, PI3K* and *MEK 1/2* is observed (see red nodes in [figure 3](#fig3){ref-type="fig"}). Second, known activators of the ERK/MAPK pathway, such as *KIT, CDC42, MRAS, CRK, FCGR2A, JAK2 and LCK* are frequently overexpressed (activator genes coloured in red). Third, downregulation of proteins that are known to directly or indirectly inhibit molecules of the pathway (ie, RHEB) is observed as well (inhibitor genes coloured in green).

![Ingenuity Pathway Analysis of differentially expressed genes of patients with no activating mutation in KRAS, BRAF and PI3KCA classified as oncogenic by the combined model (n=79) versus patients classified as wildtype-like (n=127) The ERK/MEK pathway can be activated by mutations in *KRAS*, *BRAF* or *PIK3CA (*marked with red crosses*)*. In tumours harbouring no activating mutation, the ERK/MEK pathway can be activated by (1) upregulation of *RAS, PI3K* and mitogen-activated protein kinase family genes (red nodes), (2) upregulation of activator genes (coloured in red) and (3) downregulation of inhibitor genes (coloured in green).](gutjnl-2012-302423f03){#fig3}

Interestingly, tumours with high expression levels of amphiregulin (*AREG*) and epiregulin (*EREG*), two ligands that can activate EGFR and have shown clinical relevance for the treatment of CRC patients,[@b12] clustered in the groups of patients with wildtype-like signatures ([figure 1](#fig1){ref-type="fig"}) showing an inverse correlation with the scores of the three *KRAS*, *BRAF* and *PIK3CA* oncogenic signatures (*AREG*: Pearson correlations −0.39, −0.42 and −0.47; *EREG*: −0.51, −0.53 and −0.58, respectively).

Association of the combined oncogenic pathway signature with response to cetuximab
----------------------------------------------------------------------------------

The high proportion of mutation-negative cases that were displaying an oncogenic signature gave rise to the possibility that the signature could have some predictive value in the response to cetuximab beyond the mutation status. We explored whether the signatures have predictive value in the response to cetuximab (Erbitux) treatment in patients with metastatic CRC using a publicly available dataset of 80 metastatic colon cancer patients.[@b12] Of these, information available was useful in 68 cases, 20 of them *KRAS* mutation positive. No patient had a *BRAF* mutation, and the *PI3KCA* mutation status was unknown. Tumour samples were analysed in silico for the *KRAS*, *BRAF* and *PIK3CA* signatures, and the combined signature was used to assess the association with response. As shown in the original publication,[@b17] *KRAS* mutation status is an indicator of response with wildtype patients having a better outcome than patients with activating mutations ([figure 4A](#fig4){ref-type="fig"}). The 68 tumours were ranked according to their correlation with the gene signatures and classified as activating oncogenic or wildtype-like, based on the 33-percentile. Kaplan--Meier survival analysis resulted in a significant better survival of patients classified as wildtype (n=46) compared with patients classified as oncogenic (n=22) by the gene signatures (*KRAS* signature, HR=2.62 p=0.004, logrank test; *BRAF* signature, HR=2.08 p=0.018; *PIK3CA*, HR=2.67 p=0.003; Suppl figure 1). The combined oncogenic pathway signature also showed a strong predictive value (HR=2.51 p=0.0009, [figure 4B](#fig4){ref-type="fig"}).

![Classification by *the combined signature* is associated with response to cetuximab treatment. Kaplan--Meier survival analysis of 68 metastatic colorectal cancer patients who have received cetuximab treatment.[@b12] Tumour samples have been classified in silico as wildtype-like (Group 0, blue solid line) or as oncogenic (Group 1, red dashed line) by the (A) *KRAS* mutation status, by (B) the combined signature model. In addition, survival curves are shown for classification by the combined signature model of *AREG*-high (C) and *EREG*-high (D) samples groups, and for KRAS wildtype patients only (E).](gutjnl-2012-302423f04){#fig4}

We further evaluated whether the association of the combined signature with cetuximab response was independent of amphiregulin (*AREG*) and epiregulin (*EREG*) expression levels as these two ligands have been shown to have predictive value for cetuximab response.[@b12] For this purpose, the 68 tumours were split into an *AREG*-high (n=34) and an *AREG*-low (n=34) group based on the median *AREG* expression level. Within the *AREG*-high group, the oncogenic pathway signature remained significantly associated with survival of treated patients (HR=4.06 p=0.001, [figure 4C](#fig4){ref-type="fig"}). This analysis was repeated for *EREG* expression, and also within the *EREG*-high patient group the combined signature was able to identify patients who benefited more from cetuximab treatment (HR=3.28 p=0.005, [figure 4D](#fig4){ref-type="fig"}). In contrast, classification using the combined signature showed no association with survival within the *AREG*-low (p=0.99) and *EREG*-low groups (p=0.35). These results indicate that, although classification by the gene signature model is associated with *AREG/EREG* expression, it likely holds additional predictive value to further stratify patients that benefit most from anti-EGFR-targeted therapies.

We investigated whether the predictive power of the combined oncogenic pathway signature is independent of *KRAS* mutation status. The combined classification model showed a significant performance within *KRAS* wildtype patients (HR=2.49 p=0.009, [figure 4E](#fig4){ref-type="fig"}), indicating an association with survival beyond *KRAS* wildtype status. As expected, almost all samples with a *KRAS* mutation were classified as mutation-like by the combined signature (16 of 20), and within this group the gene signature model showed no association with treatment response (p=0.63). Finally, *KRAS* status is not predictive in the 36 patients with activated oncogenic pathway (data not shown).

Discussion
==========

Three signalling pathway signatures were developed to characterise specific types of oncogenic mutations in colon cancer (*KRAS*, *BRAF* or *PIK3CA).* The results indicate that, in spite of widespread effects, tumours with these mutations display a partially shared gene expression pattern captured by our signature. The combined oncogenic pathway signature model has led to the classification of '*activating oncogenic*' tumours with a significant proportion of mutation-negative cases.

The combined oncogenic pathway signature identifies tumours with one specific mutation, but also patients with an activated EGFR pathway caused by other aberrations or by unknown activation mechanisms ([figure 5](#fig5){ref-type="fig"}). A variety of mechanisms can activate the EGFR/ERK/MAPK pathway in wildtype patients: (1) directly by upregulation of RAS, PI3K and mitogen-activated protein kinase family genes; (2) indirectly by up-regulation of activator genes, like KIT, CDC42, MRAS, CRK, FCGR2A, LCK and JAK2 or (3) by downregulation of inhibitor genes. These mechanisms of activation can only by detected by a signature that measures the effect of any downstream activation. Taken together, our data reveals novel underlying mechanism as to why a colorectal tumour with no known activating mutations in *KRAS*, *BRAF* or *PIK3CA* can display a shared gene expression pattern with mutation carriers, and explains resistance to the treatment of anti-EGFR drugs, such as cetuximab.

![Mechanism of response to anti-EGFR inhibitors. The combined oncogenic pathway signature can not only identify tumours with one specific mutation, but also patients with an activated EGFR pathway caused by other aberrations, or by unknown activation mechanisms.](gutjnl-2012-302423f05){#fig5}

In line with this observation, no particular enrichment for members of the canonical EGFR-signalling pathways is evident in the individual and combined signatures. However, a reduced number of these genes is shared, such as the members of the dual-specificity phosphatases (DUSPs) family *DUSP6* and *DUSP18*. Genes associated with the same response (ie, *DKK1*, *PHLDA1* and *SLC7A*) are also part of them. DUSP proteins shut down MAPK signalling and are involved in the late response to EGF. They play a relevant role in the negative feedback regulation of EGFR\--signalling pathway attenuating the response to EGF.[@b28] *DUSP4* and *DUSP6* were originally identified as top resistance markers to cetuximab in unselected patients[@b12] [@b29] and have also been highlighted in in vitro systems.[@b30] The use of a four-gene model, including *AREG*, *EREG*, *DUSP6* and *SLC26A3*, has been shown to improve the identification of responders among preselected *KRAS* wildtype patients.[@b29] As there is a clear association between cetuximab response and mutation status, it is not surprising that we find *DUSP6* and members of the SLC family also in the mutation signatures. Interestingly, *DUSP6* and *SLC7A* have also been shown to correlate to response to MEK inhibitors[@b31] and PI3K pathway inhibitors.[@b23]

Among the individual signatures, the *BRAF* oncogenic-specific signatures showed the most distinct gene expression pattern, and had the best performance with an overall accuracy of 91%. The more explicit *BRAF* signature identified two large distinctive groups and showed no ambiguous region when compared with *KRAS* ([figure 1A](#fig1){ref-type="fig"}) and *PIK3CA* profiling ([figure 1C](#fig1){ref-type="fig"}). As expected, a strong correlation was observed with MSI-H status. *BRAF* mutations have been described to be more frequent (40%--50%) in MSI-H patients.[@b27] The better accuracy of the *BRAF* signature may reflect its more downstream position within the *EGFR*-signalling transduction pathway. *KRAS* and *PIK3CA* are located more upstream in the EGFR-signalling cascade and may, therefore, signal to a wider range of downstream signal transduction pathways and transcriptional effects. In contrast, the further downstream-located *BRAF* may signal to a more limited number of signal transduction pathways, resulting in a more discrete gene expression pattern. In spite of its high specificity, *BRAF* signature still captures a proportion of *KRAS* mutant cases in line with the recent description of a population of *BRAF* mutated-like *KRAS* mutants.[@b32]

This combined model is associated with response to cetuximab treatment in patients with metastatic CRC with better performance than each of the three single mutation signatures and using the *KRAS* mutation status alone. This combined signature has independent value from *KRAS* mutation and *AREG* and *EREG* expression status, which are currently the major determinants of response. It can be speculated that these patients might benefit more from downstream inhibitors like MEK, AKT or PIK3CA inhibitors. In fact, signatures measuring pathway activation can identify patients who are sensitive to the pathway inhibition, and the signatures are superior to measuring the mutation status alone.[@b23] [@b31]

The finding that the signatures and the combined model are in good agreement with known markers of response to cetuximab, but offer additional information beyond those markers, confirms our hypothesis that a genomic signature might be a more comprehensive solution to identify the patients who are most likely to benefit. This might be of special interest when less well-characterised pathways are targeted, and knowledge about predictive markers is limited.

The large numbers of well-annotated early stage tumours that have been profiled have provided us with adequate power to develop and validate the signatures. The use of Sanger sequencing with RNA as a starting material is a robust and reasonably sensitive option when analysing tumour cell-enriched samples. While we are aware that some *KRAS*-positive cases may have been misclassified, we do not think that this affects the validity of our observations. The excellent correlation between the training and validation set and the strong biological plausibility of the signature genes has confirmed the potential of using simple predictors and simple reporter-selection strategies.[@b33] The utility of the profile still needs further validation in patients treated with EGFR-pathway inhibitors. Finally, it will be of interest to know whether these profiles will be useful in the prediction of response of the novel compounds that inhibit the EGFR pathway further downstream, that is, at the level of PI3K, BRAF, MEK or mTOR.
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